Halazepam

Summary

Halazepam (CHEMBL970) is an approved small molecule (ATC N05BA13); indicated across 1 condition including anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05BA13
• Indications: 1 condition
• Chemistry: 352.7 Da · C17H12ClF3N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL970
Name	Halazepam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	31640
ATC	N05BA13
Molecular formula	C17H12ClF3N2O
Molecular weight	352.7
InChIKey	WYCLKVQLVUQKNZ-UHFFFAOYSA-N

SMILES: C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3)CC(F)(F)F

IUPAC name: 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one

Also known as: Halazepam, Halazepam civ, Paxipam, SCH 12041, SCH-12041, HALAZEPAM, halazepam

Patent coverage: 2,431 distinct patent families (9,882 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 9,760 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Mu-type opioid receptor, Kappa-type opioid receptor, Adenosine receptor A3, Nuclear receptor subfamily 1 group I member 2, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62813	6.3	AC50	505.7	nM	CHEMBL_ACT_25130752
OPRM1	5.92	AC50	1200	nM	CHEMBL_ACT_25147016

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	4	MONDO:0011918	EFO:0005230

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).